UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 26,524 Shares of Twist Bioscience Co. (NASDAQ:TWST)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 853,675 shares of the company's stock after selling 26,524 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.43% of Twist Bioscience worth $39,670,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. First Light Asset Management LLC purchased a new position in shares of Twist Bioscience during the fourth quarter valued at approximately $56,984,000. Marshall Wace LLP boosted its holdings in Twist Bioscience by 15,927.8% in the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock worth $39,319,000 after purchasing an additional 840,828 shares during the last quarter. Thrivent Financial for Lutherans grew its position in Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after purchasing an additional 532,040 shares during the period. Jennison Associates LLC raised its stake in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock valued at $31,636,000 after buying an additional 302,884 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Twist Bioscience by 63.5% during the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock valued at $35,148,000 after buying an additional 293,751 shares during the period.

Twist Bioscience Price Performance

TWST stock traded down $1.08 during trading on Wednesday, reaching $28.33. The company's stock had a trading volume of 1,142,745 shares, compared to its average volume of 978,754. The company has a market capitalization of $1.70 billion, a P/E ratio of -8.38 and a beta of 2.54. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The company's fifty day moving average is $36.19 and its 200-day moving average is $42.60. Twist Bioscience Co. has a 1 year low of $27.12 and a 1 year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. On average, research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Barclays cut their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Robert W. Baird dropped their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group reduced their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Finally, Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $50.40.

Insider Transactions at Twist Bioscience

In related news, SVP Paula Green sold 918 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the sale, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. The trade was a 0.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 1,726 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the transaction, the chief executive officer now directly owns 660,966 shares of the company's stock, valued at approximately $27,549,062.88. The trade was a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,850 shares of company stock valued at $974,764. 3.01% of the stock is currently owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.